U.S. and Low- and Middle-Income Country (LMIC) HIV-Associated Malignancy Research Centers (U54 Clinical Trial Optional)

The summary for the U.S. and Low- and Middle-Income Country (LMIC) HIV-Associated Malignancy Research Centers (U54 Clinical Trial Optional) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

U.S. and Low- and Middle-Income Country (LMIC) HIV-Associated Malignancy Research Centers (U54 Clinical Trial Optional): The purpose of this Funding Opportunity Announcement (FOA) is to support research on human immunodeficiency virus (HIV)-associated cancers in low- and middle-income countries (LMICs) through the formation of collaborative partnerships between investigators in United States (U.S.) and investigators in LMICs. The FOA solicits applications for Specialized Center Cooperative Agreements (U54) for research on HIV-associated cancers from research institutions in the U.S. and LMICs. These partnerships are referred to as HIV-Associated Malignancy Research Centers (HAMRCs). Each proposed U54 HAMRC should be based upon partnerships involving at least one U.S. institution and institutions from at least two or more LMICs. Each HAMRC application is required to propose between two to three research projects that address questions in one scientific theme (e.g. viral-associated cancers) that is relevant to HIV-associated malignancies in LMICs or the U.S. The proposed projects may range, as appropriate, from basic research to translational efforts as well as to population and implementation studies. Mechanistic clinical studies that meet NIH's definition of a clinical trial will be allowed. In addition, the proposed U54 HAMRC must include an Administrative Core and a Developmental Core.

Federal Grant Title:	U.S. and Low- and Middle-Income Country (LMIC) HIV-Associated Malignancy Research Centers (U54 Clinical Trial Optional)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Education Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-CA-22-011
Type of Funding:	Cooperative Agreement
CFDA Numbers:	93.393, 93.394, 93.395, 93.396, 93.989
CFDA Descriptions:	Information not provided
Current Application Deadline:	March 30th, 2022
Original Application Deadline:	March 30th, 2022
Posted Date:	January 3rd, 2022
Creation Date:	January 3rd, 2022
Archive Date:	May 5th, 2022
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	January 24th, 2022

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-22-011.html
Grant Announcement Contact: NIH OER Webmaster
[email protected]
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Similar Government Grants: • Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional); • Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required); • National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer ...; • Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Cli...; • Early-Stage Development of Informatics Technologies for Cancer Research and Management (U0...; • Pilot Studies in Pancreatic Cancer; • Cancer Prevention Research Small Grant Program; • Molecular Targets for Nutrients in Prostate Cancer Prevention
More Grants from the National Institutes of Health: • Small Business Transition Grant for New Entrepreneurs (R43/R44 Clinical Trial Required); • Independent Scientist Award (Parent K02 Independent Basic Experimental Studies with Humans...; • Coordinating Center for Type 1 Diabetes TrialNet (U01 Clinical Trial Required); • NHLBI Emerging Investigator Award (EIA) (R35 Clinical Trial Optional); • NHLBI Outstanding Investigator Award (OIA) (R35 Clinical Trial Optional)